Category: Press Release - Page 163 - Psychedelic Alpha

Explore our new Pα+ Psychedelic Bill Tracker.

Read more about the article Lobe Sciences Announces Management Changes and New Director

Lobe Sciences Announces Management Changes and New Director

Post published:January 18, 2021
Post category:Press Release

Read more about the article Cybin Announces CDN$20 Million Bought Deal Offering

Cybin Announces CDN$20 Million Bought Deal Offering

Post published:January 18, 2021
Post category:Press Release

Read more about the article Optimi Health Corp. Receives Health Canada Psychedelic Research Exemption and Files Preliminary Prospectus for Initial Public Offering of Units

Optimi Health Corp. Receives Health Canada Psychedelic Research Exemption and Files Preliminary Prospectus for Initial Public Offering of Units

Post published:January 15, 2021
Post category:Press Release

Read more about the article Awakn Life Sciences Appoints CRO to Conduct Phase II Study of MDMA as a Treatment for Alcohol Use Disorder

Awakn Life Sciences Appoints CRO to Conduct Phase II Study of MDMA as a Treatment for Alcohol Use Disorder

Post published:January 15, 2021
Post category:Press Release

Numinus Announces Grant of Stock Options

Post published:January 14, 2021
Post category:Press Release

Read more about the article CBDV Begins Research on Psilocybin with Section 56 Exemption from Health Canada

CBDV Begins Research on Psilocybin with Section 56 Exemption from Health Canada

Post published:January 14, 2021
Post category:Press Release

Read more about the article Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units

Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units

Post published:January 14, 2021
Post category:Press Release

Read more about the article Entheon Biomedical Corp. Announces Acquisition of HaluGen Life Sciences Inc.

Entheon Biomedical Corp. Announces Acquisition of HaluGen Life Sciences Inc.

Post published:January 14, 2021
Post category:Press Release

Read more about the article Revive Therapeutics Announces Research Collaboration with North Carolina State University for Natural Biosynthesis Enzymatic Platform To Develop Psilocybin

Revive Therapeutics Announces Research Collaboration with North Carolina State University for Natural Biosynthesis Enzymatic Platform To Develop Psilocybin

Post published:January 14, 2021
Post category:Press Release

Read more about the article MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience

Post published:January 14, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.